Aino Health (AINO) Q4 2024 earnings summary

Executive summary

• Net sales for Q4 2024 were KSEK 6,000, slightly down from KSEK 6,313 in Q4 2023; full-year net sales reached KSEK 23,941, nearly flat year-over-year.

• Loss after financial items improved to KSEK -3,451 in Q4 2024 from KSEK -3,851 in Q4 2023; full-year loss after financial items was KSEK -9,915, an improvement from KSEK -10,661 in 2023.

• SaaS user base grew to 112,000 by year-end 2024, reflecting continued customer acquisition and expansion, especially in Finland.

• Three new public sector organizations in Finland adopted the SaaS platform in Q4, strengthening the company’s position in the public sector.

Financial highlights

• Operating result for Q4 2024 was KSEK -3,225, compared to KSEK -3,458 in Q4 2023.

• Cash flow for Q4 2024 was KSEK -787, an improvement from KSEK -1,932 in Q4 2023.

• Equity ratio stood at -5% as of December 31, 2024, indicating a negative equity position.

• Earnings per share for the full year were SEK -0.1, up from SEK -0.2 in 2023.

• Number of shares increased significantly to 204,569,103 by year-end 2024 due to a rights issue.

Outlook and guidance

• Liquidity is expected to improve in the first half of 2025 as new contracts become effective.

• Anticipates increased user numbers and strengthened cash flow in 2025, driven by new customer agreements and expansion strategy.